Eighty-five consecutive patients undergoing rheumatic valve surgery were enrolled and randomly assigned to an irbesartan plus amiodarone ( irbesartan 150 mg/d , n = 43 ) or an amiodarone group ( n = 42 ) starting 10 days before scheduled electrical cardioversion .
